86 
1 and discrepancies between institutions. Approximately 
2 ten to fifteen percent of all MUA's are disapproved by the 
3 NIH on non-trivial grounds. This creates ample opportunity 
4 for problems . 
5 Recommendation. Require prior NIH approval 
6 on non-trivial changes on P2 through P4. If significant 
7 delays develop, hire more staff, fund less research — 
8 one staff person worth. 
9 The IBC's approve single-step reductions in 
10 containment levels for experiments with purified DNA 
11 and characterized clones. Authority for single-step 
12 reductions in containment levels, as well as the previous 
13 provision, will lead to a patchwork of regulations, which 
14 was decried by the scientific community in regards to 
15 federal preemption of stricter standards but is 
16 apparently welcomed for lowering them. Furthermore, there 
17 is no requirement that these fully characterized clones 
18 or purified DNA be safer. 
19 
MR. LIBASSI: 
Do 
we have 
your 
full statement? 
20 
MS. LIPPE: 
Yes , 
you do. 
21 
MR. LIBASSI: 
All 
right. 
thank 
you very much. 
22 We will get the rest of it there. 
23 Jonathan King? Why don't you go ahead now. 
24 DR. KING: Good morning. Thank you for this 
25 opportunity to testify. My name is Jonathan King. I am 
[178] 
